





## Pseudomonas aeruginosa – Sepsis (peritonitis)

#### **Procedure Summary**

- Immunocompetent CD-1 mice, eight weeks old females
- Pseudomonas aeruginosa DSM 1117
- Bacterial challenge by intraperitoneal route
- Mucin 5%
- Reference compound: Tobramycin (SC)

## **Experimental readouts**

- Survival rate
- Weight loss
- Clinical score

### **Optional Services**

- CFU determination (peritoneal fluid, spleen...)
- Cytokine and chemokine analysis
- Pharmacokinetics

### **Animal Welfare**

• Each experimental protocol is approved by the local ethics committee for animal experimentation of Grand Campus Dijon (Burgundy, France) and performed in accordance to the current recommendations of the European Institute of Health EU Directive 86/609


#### **Facilities**

• These assays are performed at our BSL2 laboratory / zootechnical center in Dijon, France

### Reference

- Internal Data
- Scholl *et al.*, AAC 2008 "Antibacterial efficacy of R-Type pyocins towards *Pseudomonas aeruginosa* in a murine peritonitis model"

# Efficacy of tobramycin on survival rate in a murine model of septicaemia induced by *Pseudomonas aeruginosa* DSM 1117



Our scientific team will readily accomodate client-specific alterations and will provide expert advice and guidance for your efficacy studies

#### For more information please contact: info@vivexia.fr